Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Clin Cancer Res. 2021 Nov 2;28(2):414–424. doi: 10.1158/1078-0432.CCR-21-1535

Figure 2. Cholesterol-lowering decreases mTOR signaling in lymphocytes and increased markers for central CD8+ T cell memory.

Figure 2.

A. Serum cholesterol levels were measured in mice treated with ezetimibe (n=6). B. CD8+ Splenocytes from ezetimibe-treated mice showed decreased AKT/mTOR signaling, with pronounced decrease in phosphorylation of AKT at Ser473. Representative blots from duplicate experiments are shown. C. pAKT (Ser473) in CD8+ lymphocytes from patients before and after cholesterol lowering (CL) with statin+ezetimibe was measured by flow cytometry (n=4). D. Human pAKT (Ser473) in CD8+ lymphocytes in these patients was significantly reduced by CL. E. RM1 prostate adenocarcinoma cells were injected into B6 mice (8-9 mice/group) and ezetimibe treatments were started 3 days later. Tumor growth was monitored and p-value was obtained by using the repeated measures ANOVA. F-I. Lymphocytes were collected from mice treated with ezetimibe or saline for 21 days and analyzed for the indicated markers by flow cytometry. G. Splenocytes were first gated for CD8 prior to flow cytometry analysis for the indicated markers. Error bars represent standard error.